Literature DB >> 17569475

[Recommendations for clinical practice. Therapeutic choices for rectal cancer. How should neoadjuvant therapies be chosen?].

Guillaume Portier1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17569475

Source DB:  PubMed          Journal:  Gastroenterol Clin Biol        ISSN: 0399-8320


× No keyword cloud information.
  5 in total

1.  Laparoscopic surgery for rectal cancer: preoperative radiochemotherapy versus surgery alone.

Authors:  Quentin Denost; Christophe Laurent; Thomas Paumet; Laurence Quintane; Mathieu Martenot; Eric Rullier
Journal:  Surg Endosc       Date:  2012-01-05       Impact factor: 4.584

2.  Risk factors for circumferential R1 resection after neoadjuvant radiochemotherapy and laparoscopic total mesorectal excision: a study in 233 consecutive patients with mid or low rectal cancer.

Authors:  Clotilde Debove; Léon Maggiori; Amélie Chau; Frédéric Kanso; Marianne Ferron; Yves Panis
Journal:  Int J Colorectal Dis       Date:  2014-12-04       Impact factor: 2.571

3.  Potential sexual function improvement by using transanal mesorectal approach for laparoscopic low rectal cancer excision.

Authors:  Arnaud Pontallier; Quentin Denost; Bart Van Geluwe; Jean-Philippe Adam; Bertrand Celerier; Eric Rullier
Journal:  Surg Endosc       Date:  2016-03-04       Impact factor: 4.584

4.  Transanal versus abdominal low rectal dissection for rectal cancer: long-term results of the Bordeaux' randomized trial.

Authors:  Quentin Denost; Paula Loughlin; Remy Chevalier; Bertrand Celerier; Romain Didailler; Eric Rullier
Journal:  Surg Endosc       Date:  2017-10-24       Impact factor: 4.584

5.  A multicentric randomized controlled trial on the impact of lengthening the interval between neoadjuvant radiochemotherapy and surgery on complete pathological response in rectal cancer (GRECCAR-6 trial): rationale and design.

Authors:  Jérémie H Lefevre; Alexandra Rousseau; Magali Svrcek; Yann Parc; Tabassome Simon; Emmanuel Tiret
Journal:  BMC Cancer       Date:  2013-09-12       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.